Switch theme
Sign up to access all valuation multiples
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
2008
78
Last FY Revenue n/a
LTM EBITDA -$131M
$74.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Astria Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$131M.
In the most recent fiscal year, Astria Therapeutics achieved revenue of n/a and an EBITDA of -$112M.
Astria Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Astria Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$131M | XXX | -$112M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$127M | XXX | -$112M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$112M | XXX | -$94.3M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Astria Therapeutics's stock price is $5.
Astria Therapeutics has current market cap of $269M, and EV of $74.5M.
See Astria Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $74.5M | $269M | XXX | XXX | XXX | XXX | $-1.92 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Astria Therapeutics has market cap of $269M and EV of $74.5M.
Astria Therapeutics's trades at n/a EV/Revenue multiple, and -0.7x EV/EBITDA.
Equity research analysts estimate Astria Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Astria Therapeutics has a P/E ratio of -2.4x.
See valuation multiples for Astria Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $269M | XXX | $269M | XXX | XXX | XXX |
| EV (current) | $74.5M | XXX | $74.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.6x | XXX | -0.7x | XXX | XXX | XXX |
| EV/EBIT | -0.6x | XXX | -0.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.4x | XXX | -2.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAstria Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.4M for the same period.
Astria Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Astria Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Astria Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 28% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Astria Therapeutics acquired XXX companies to date.
Last acquisition by Astria Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Astria Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Astria Therapeutics founded? | Astria Therapeutics was founded in 2008. |
| Where is Astria Therapeutics headquartered? | Astria Therapeutics is headquartered in United States of America. |
| How many employees does Astria Therapeutics have? | As of today, Astria Therapeutics has 78 employees. |
| Who is the CEO of Astria Therapeutics? | Astria Therapeutics's CEO is Dr. Jill C. Milne, PhD. |
| Is Astria Therapeutics publicy listed? | Yes, Astria Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Astria Therapeutics? | Astria Therapeutics trades under ATXS ticker. |
| When did Astria Therapeutics go public? | Astria Therapeutics went public in 2015. |
| Who are competitors of Astria Therapeutics? | Similar companies to Astria Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Astria Therapeutics? | Astria Therapeutics's current market cap is $269M |
| Is Astria Therapeutics profitable? | Yes, Astria Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Astria Therapeutics? | Astria Therapeutics's last 12 months EBITDA is -$131M. |
| What is the current EV/EBITDA multiple of Astria Therapeutics? | Current EBITDA multiple of Astria Therapeutics is -0.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
